Implementing Levodopa‐Carbidopa Intestinal Gel for Parkinson Disease: Insights from US Practitioners

BACKGROUND: Levodopa‐carbidopa intestinal gel (LCIG, designated in the United States as carbidopa‐levodopa enteral suspension, CLES) was approved in the United States in 2015 for the treatment of refractory motor fluctuations in individuals with Parkinson disease (PD). Many neurologists in the Unite...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mov Disord Clin Pract
Main Authors: Burack, Michelle, Aldred, Jason, Zadikoff, Cindy, Vanagunas, Arvydas, Klos, Kevin, Bilir, Bahri, Fernandez, Hubert H., Standaert, David G.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Reviews
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6174493/
https://ncbi.nlm.nih.gov/pubmed/30363427
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mdc3.12630
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados